DS-8201

Progression-Free Survival Increased Fivefold, Intracranial Response Rate at 65.7%! ‘Miraculous Anti-Cancer Drug’ Solves the Treatment Challenge of Breast Cancer Brain Metastases

by
Progression-Free Survival Increased Fivefold, Intracranial Response Rate at 65.7%! 'Miraculous Anti-Cancer Drug' Solves the Treatment Challenge of Breast Cancer Brain Metastases

What else can DS-8201 not do? Recently, the “miraculous anti-cancer drug” DS-8201 announced data from its DESTINY-Breast03 trial involving patients with brain metastases[1]: Among 43 patients with HER2-positive breast cancer brain metastases treated with DS-8201, the median progression-free survival reached 15.0 months, with intracranial objective response rate and overall objective response rate at 65.7% and … Read more

Lancet Oncology Publishes! Efficacy and Safety of DS-8201 in Treating HER2-Positive Lung Cancer

by
Lancet Oncology Publishes! Efficacy and Safety of DS-8201 in Treating HER2-Positive Lung Cancer

Source: Professor Zhang Bo The activation mechanisms of the HER-2 gene include amplification, mutation, insertion, and protein overexpression. Although HER-2 is considered a driver gene in lung cancer, no targeted therapeutic drugs have been approved. Recently, Lancet Oncology published efficacy and safety data for the ADC drug DS-8201 targeting HER2 in patients with advanced NSCLC … Read more

ESMO: DS-8201 Advances in Second-Line Treatment for HER2-Positive Gastric Cancer

by
ESMO: DS-8201 Advances in Second-Line Treatment for HER2-Positive Gastric Cancer

On September 10, 2022, updated data from the open-label, multicenter Phase II DESTINY-Gastric02 study were presented at the ESMO conference, showing that DS-8201 demonstrated sustained clinical benefits and acceptable safety in patients with locally advanced or metastatic HER2-positive gastric cancer or gastroesophageal junction (GEJ) cancer who had previously received trastuzumab-based therapy. The study included 79 … Read more

Hengrui SHR-A1811: Soaring Higher on the Shoulders of DS-8201

by
Hengrui SHR-A1811: Soaring Higher on the Shoulders of DS-8201

Focused and dedicated, stepping onto the international stage Written by|Little Medicine Monster The latest generation of anti-HER-2 ADC drug developed by Hengrui, SHR-A1811, is often jokingly referred to as the domestic alternative to DS-8201 due to its similar structure. However, strength will eliminate all rumors. Results from early clinical studies released by AACR this year … Read more

Exciting News: DS-8201 Brings New Hope for HER2 Positive Breast Cancer Patients!

by
Exciting News: DS-8201 Brings New Hope for HER2 Positive Breast Cancer Patients!

With the advancement of breast cancer treatment, there are increasingly more life-saving drugs available for patients. The emergence of new treatment methods is like a relay race, passing on the hope of life, even in the face of recurrence and metastasis, it is no longer a dead end. In the past, anti-HER2 treatments saved countless … Read more